Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 9/20 | 0.47 |
| ▸ | THRB | P10828 | 6/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1175437 | 0.86 | CNR2 (0.58) | GAACNR2MEN1CYP1A2CYP3A4 | |
| SCHEMBL1175441 | 0.86 | CNR2 (0.58) | GAACNR2MEN1CYP1A2CYP3A4 | |
| SCHEMBL1175541 | 0.85 | CNR2 (0.44) | GAACNR2MEN1CYP1A2CYP3A4 | |
| SCHEMBL1175537 | 0.85 | CNR2 (0.44) | GAACNR2MEN1CYP1A2CYP3A4 | |
| SCHEMBL1174239 | 0.82 | CNR2 (0.45) | GAACNR2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1174243 | 0.82 | CNR2 (0.45) | GAACNR2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1174379 | 0.81 | CNR2 (0.45) | GAACNR2MEN1KMT2AMAPT | |
| SCHEMBL1174377 | 0.81 | CNR2 (0.45) | GAACNR2MEN1KMT2AMAPT | |
| SCHEMBL12866702 | 0.81 | GAA (0.65) | GAACNR2MEN1CYP1A2CYP3A4 | |
| SCHEMBL10091035 | 0.78 | CNR2 (0.77) | GAACNR2MEN1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859538-B2 | Uses of substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20110034443-A1 | USES OF SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034443-A1 | USES OF SUBSTITUTED IMIDAZOHETEROCYCLES | CNR2, CNR1, TRPV1 | GAA 3789/4885CNR2 1/4885MEN1 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.